(en traduction)

Jonathan Angel, MD
Core Co-Leader, Vaccines and Immunotherapies

Dr. Angel graduated from medical school at the University of Toronto in 1988, which was followed by an internal medicine residency in Toronto. After one year as the chief medical resident at St. Paul’s Hospital in Vancouver, he did his clinical and research infectious diseases training at the New England Medical Center/Tufts University in Boston.

Read more

Since joining the Division of Infectious Diseases, Department of Medicine at the Ottawa General Hospital in 1995, Dr. Angel has been involved in laboratory based and clinical research as well as teaching and patient care. His research is focused on understanding how HIV damages the immune system and how these insights can potentially lead to new therapies.

Dr. Angel is currently a professor of medicine at the University of Ottawa, a senior scientist in the Ottawa Hospital Research Institute and the director of the HIV Clinic at the Ottawa Hospital.

Curtis Cooper, MD
Core Co-Leader, Co-infections and Concurrent Diseases

Dr. Curtis Cooper, The Ottawa Hospital, was appointed co-leader of the Co-infections and Concurrent Diseases Core in 2010.

Read more

Dr. Curtis Cooper trained at the University of Saskatchewan (MD 1994). He received certification in Internal Medicine in 1997 and in Infectious Diseases in 1999 while at the University of Manitoba. He completed an HIV Research Fellowship and Masters of Epidemiology in 2002 while at the University of Ottawa.

He is currently an Associate Professor with the University of Ottawa, Infectious Diseases Consultant with the Ottawa Hospital Division of Infectious Diseases, Associate Clinical Researcher with the Ottawa Health Research Institute, Director of the Ottawa Hospital and Regional Viral Hepatitis Program and an Executive Board Member with the Canadian Association for HIV Research.

As a clinical researcher, his research activities encompass HIV, viral hepatitis, and vaccine development. His work is focused on the development of new therapeutic agents and the delivery of treatment that maximizes safety, adherence and safety.

Marina Klein, MD
National Co-Director
Core Co-Leader, Co-infections and Concurrent Diseases

Dr. Marina Klein of the McGill University Health Centre in Montreal was appointed Co- Leader of the Co-infections and Concurrent Diseases Core in 2009. In addition to this role, she is also a national co-director of the CTN.

Read more

Dr. Klein graduated from McGill Medical School in 1991 and received her training in internal medicine at the Royal Victoria Hospital from 1991-1994. After completing a research fellowship in infectious diseases at the University of Minnesota in 1998 she returned to McGill University to join the Division of Infectious Diseases/Chronic Viral Illness Service at the Royal Victoria Hospital. While on faculty she received a Master’s degree in epidemiology and biostatistics from McGill. She is a former postdoctoral fellow of the CIHR Canadian HIV Trials Network and a previous recipient of an MRC/CIHR New Investigator award. She is currently supported by a “Chercheur National” Award from the FRQ-S.

Dr. Klein focuses her research on clinical and epidemiologic aspects of HIV and hepatitis C co-infection and leads a CIHR-funded prospective cohort study of co-infected patients to study the interaction of these chronic viral infections. She is also a principal investigator for clinical trials in the treatment of co-infection. Additional research interests include observational database research in pharmacoepidemiology of antiretrovirals, HIV infection in women and non-clade B HIV populations.

Mona Loutfy, MD, FRCPC, MPH
Core Co-Leader, Prevention and Vulnerable Populations

Dr. Mona Loutfy, Women’s College Research Institute, Women’s College Hospital, University of Toronto, was appointed co-leader of the Prevention and Vulnerable Populations Core in 2012.

Read more

Dr. Loutfy graduated from the University of Toronto Medical School in 1995 and she received her training in Internal Medicine also at the University of Toronto from 1995-99. After completing a clinical fellowship in Infectious Diseases at the University of Toronto, Dr. Loutfy obtained a Master’s Degree in Public Health from the Harvard School of Public Health. Following that she held a Postdoctoral Fellowship with the CIHR Canadian HIV Trials Network.

Dr. Loutfy is currently an Associate Professor in the Department of Medicine at the Women’s College Hospital and she heads the Women and HIV Research Program at the Women’s College Research Institute. She is also the research director at the Maple Leaf Medical Clinic (MLMC), Canada’s largest private HIV practice.

As a leader in HIV research and care in Canada, Dr. Loutfy’s research is focused on the clinical management of HIV infection in women. Her work has brought forward innovations such as the Canadian HIV Pregnancy Planning Guidelines. She is committed to breaking down HIV-related stigma and works directly with communities to ensure that research agendas are relevant and prioritize the needs of vulnerable populations. Currently, Dr. Loutfy is furthering this work as a Co-Principal Investigator for a large CIHR-funded clinical trial assessing health service disparities for women living with HIV across regional and demographic contexts in Canada (CTN 262 – the CHIWOS study). Dr. Mona Loutfy is also a member of the CTN’s Steering Committee.

In July 2014, Dr. Loutfy received her medical license to practice in Saskatchewan where she now travels to bi-monthly to care for Indigenous women with HIV and their partners who live in rural and northern communities. In 2015, she received an Adjunct Professor appointment at the First Nations University of Canada. Dr.Loutfy works from a community-based research model involving the people that her research will affect at all stages.

Jean-Pierre Routy, MD
Core Co-Leader, Vaccines and Immunotherapies

A former CTN postdoctoral fellow, Dr. Jean-Pierre Routy was appointed co-leader of the Vaccines and Immunotherapies Core in 2008. He is also a member of the CTN Steering Committee.

Read more

Dr. Routy received his MD in 1986 and completed his residency in Hematology-Oncology at the Université d’Aix-Marseille, France. In 1992, he was awarded a fellowship from the Université de Montréal and from the CIHR Canadian HIV Trials Network to conduct hematological and immunological research in HIV-infected patients.

As director of the Quebec Primary HIV-Infection Study since 1996, Dr. Routy has contributed to research on HIV transmission of drug resistance and HIV pathogenesis. Since 1999, he holds a scientific career award as a Physician-Scientist from the <em>Fonds de Recherche en Santé du Quebec</em> (FRSQ) for his research on HIV-infection. In addition, he is involved in numerous national and international clinical trials including research on the use of valproic acid, Interleukin-7 and dendritic cell therapy for HIV infected patients.

Dr. Routy is a clinical associate professor of medicine at McGill University in Montreal, and an active member of the Division of Hematology and Immunodeficiency Service at the Royal Victoria Hospital in Montreal. He became director of the Flow Cytometry Laboratory at the Royal Victoria Hospital and in 2002, was promoted to associate professor in the Department of Medicine and Experimental Medicine. Dr. Routy is also chair of the Ethics Committee at the Royal Victoria Hospital and has recently developed important research on the ethical challenges associated with HIV transmission and antiretroviral therapy. In addition, he has authored and co-authored more than 100 publications which have appeared in high impact journals, such as New England Journal of Medicine, Lancet, Nature Medicine, Blood and AIDS.

Fiona Smaill, MBChB, FRCPC
Core Co-Leader, Clinical Management Science

Dr. Fiona Smaill, McMaster University, was appointed co-leader of the Clinical Management Sciences Core in 2012.

Read more

After earning a medical degree at Otago University in New Zealand in 1978 and completing General Medicine training at Wellington Hospital, Dr. Smaill did residencies in Internal Medicine, Infectious Diseases and Medical Microbiology at McMaster University, where she is now a Professor in the Department of Pathology and Molecular Medicine.

She is also a medical microbiologist with the Hamilton Regional Laboratory Medicine Program, a consultant in Infectious Diseases and Infection Control, and a co-director of the HIV clinic at Hamilton Health Sciences. She has her MSc in Epidemiology from McMaster University.

Dr. Smaill served on the CTN’s Scientific Review Committee from 1998 to 2009 and was the committee chair from 2005 to 2009. Dr. Smaill is actively involved in clinical trials in HIV management, the development of vaccines for tuberculosis, and management of infections in pregnancy. Her interest in HIV infection includes multicentre trials to evaluate efficacy and side effects of different antiretroviral regimens particularly related to cardiovascular disease, HIV in aging and work on gender differences in the management of HIV infection.

Sharon Walmsley, MD, MSc, FRCPC
National Co-Director
Core Co-Leader, Clinical Management Science

Dr. Sharon Walmsley is a national co-director of the CTN. In addition to this role, she is the co-leader for the Clinical Management Science Core, as well as the CTN site director for the Toronto General Hospital.

Read more

Dr. Walmsley obtained her medical degree from the University of Western Ontario. She has completed specialty training in Infectious Diseases, Microbiology and Internal Medicine and has a Master’s degree in Clinical Epidemiology from the University of Toronto.

Dr. Walmsley has participated in the pivotal trials of a number of the antiretroviral agents both for treatment-naïve and treatment-experienced patients, and has published widely in the field. She also has interest in the management of HIV infected women. She is a teacher and speaker on many HIV related issues, and supervises masters and PhD students in clinical epidemiology on HIV-related projects.

A former member of the governing council of the International AIDS Society, she was the Clinical Sciences co-chair for the World AIDS conference in Toronto, August 2006, and in 2013 in Kual a Lumpur. She is a member of the Steering Committee of the Workshop on Adverse Reactions and Lipodystrophy in HIV. She is member of the Scientific committee for the international workshop on women and HIV.

At the Toronto Hospital, University Health Network, Dr. Walmsley is a professor of medicine in the Division of Infectious Diseases, assistant director of the Immmunodeficiency Clinic, and director of the Clinical Research Program. She is  a member of the Scientific Review Committee of the Canadian Association for HIV Research. She is a senior scientist with the Toronto General Hospital Research Institute. Her receipt of a career support award from the Ontario HIV Treatment Network enables her to continue her research in the area of HIV clinical management.

Catherine Worthington, PhD
Core Co-Leader, Prevention and Vulnerable Populations

Dr. Catherine (Cathy) Worthington, University of Victoria, was appointed co-leader of the Prevention and Vulnerable Populations Core in 2011.

Read more

Dr. Worthington obtained a BAS from Trent University, followed by an MSc in Health Administration, a PhD in Social Work, and a Post-doctorate in Public Health Sciences from the University of Toronto. Currently, she is a professor at the School of Public Health and Social Policy at the University of Victoria.

Dr. Worthington conducts research on community health and social services for underserved populations, and has worked on studies that contribute to HIV prevention and care in collaboration with AIDS service organizations, people living with HIV, street-involved youth, Aboriginal organizations, and African immigrant communities. Her current work focuses on HIV and housing, stigma, training and mentoring, and community-engaged research methods.

Additional interests include HIV research ethics, the development of HIV social research methods, and engaging new researchers in the field of HIV research.

She has served on the CIHR HIV/AIDS Research Advisory Committee (CHARAC), and also acted as Social Sciences Track councilor for the Canadian Association for HIV Research (CAHR). Dr. Worthington is a principal investigator with the CIHR Social Research Centre in HIV Prevention (SRC), and chairs the Education Committee of the Centre for REACH (Research Evidence in Action for Community Health) in HIV/AIDS.

Latest News

Dr Mark Wainberg

| Uncategorized | No Comments

Le personnel et la direction du Réseau offrent leurs sincères condoléances à l’occasion du décès du Dr Mark Wainberg. Mark…

Postdoctorat en vedette : Dr Malika Sharma

| Uncategorized | No Comments

Les taux de VIH au Canada continuent d’augmenter malgré les nouveaux outils à notre portée pour prévenir les nouvelles infections….

CTN 302 : Visualiser la santé II

| Uncategorized | No Comments

Améliorer la santé des femmes autochtones séropositives par le biais de recherches culturellement enracinées et guidées par les arts La…

Appel de candidatures : comité consultatif auprès de la communauté (CCC)

| Uncategorized | No Comments

Le CCC est actuellement à la recherche de candidats pour combler plusieurs postes sur les neuf qui le composent et un poste d’apprenti.